Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.


Fox Chase Cancer Center Welcomes Dr. Melissa McShane

September 1, 2021

PHILADELPHIA (September 1, 2021) – Fox Chase Cancer Center is pleased to announce the hiring of Melissa McShane, MD, who will join the Breast Cancer Medical Oncology Program as an attending physician.

McShane will begin work following completion of the Fox Chase-Temple University Hematology/Oncology Fellowship Program. In 2020, she was named chief fellow of the program.

Prior to joining the center’s team, she worked as an oncology hospitalist in the Bone Marrow Transplant Unit of the University of Virginia, where she also completed her medical residency in internal medicine.

McShane graduated cum laude from the Sidney Kimmel Medical College at Thomas Jefferson University in 2014. While attending the university, she was inducted into multiple honors societies and received the Arnold R. Weitz, MD, Memorial Award in Hematology and the Foerderer Award for International Study.

As an undergraduate, she attended the University of Pittsburgh and graduated summa cum laude with a bachelor of science in biology degree.

McShane is a member of the American Medical Association, the American College of Physicians, the American Society of Clinical Oncology, and the American Society of Hematology.

McShane’s ongoing studies center around her specialization in breast cancer. Her research focus includes a retrospective analysis of the effectiveness of alternating mammogram and magnetic resonance imaging every six months for screening women at high risk for breast cancer, treatment patterns of older adults with metastatic breast cancer, and a case report on the response to checkpoint inhibition in a patient with metastatic HER2-positive breast cancer.

She will begin her position at Fox Chase on September 1, 2021.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Connect with Fox Chase